Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

New Products In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

InSightec, TriVascular and NicOx are among firms with notable recent product approvals or launches.

You may also be interested in...



InSightec Wins Funding, New Management From GE Healthcare

Newly appointed InSightec chairman is GE Healthcare Systems’ CEO Tom Gentile. Israeli firm’s new CEO is former GE exec Jim Davis.

Trial Investigates Focused Ultrasound For Parkinson's Disease Tremor

Clinicians discuss a feasibility trial of InSightec's focused ultrasound technology to reduce tremor related to Parkinson’s disease and a registry to show the effectiveness of focused ultrasound in treating uterine fibroids.

New Products In Brief

Table

View full table

Related Content

Medtech Insight

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application

See All
UsernamePublicRestriction

Register

MT031690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By